The float is very small, so if you increase the amount of shares out there on the open market, you will have more buyers and sellers. As for institutions or hedges, there might be pre-negotiated deals they might offer 15 million shares for like 11 a share.
To pay for P3 trial, increase trading activity. Allow more institutions to buy more stock. Raise capital with out increasing debt. Allow for a partner to join in the fun. This is a high stakes game of chess, I trust that Dr. Kim had this planned out.
It will my 3rd as well and the reverse split. But remember the S-3 last year for 2.90 when the stock was trading at 3.95, it gave us a good baseline for a while.
Hey Ino longs I just put 2 and 2 together, there will be some dillution coming in the fomr of 175 Million, that should be enough to cover the P3 expenses unless another Pharma wants to take that burden... just saying.
Virological clearance of HPV 16 or 18 from the cervix in conjunction with histopathological regression of cervical dysplasia to CIN1 or no disease, a secondary endpoint of the trial, was observed in 43 of 107 (40.2%) VGX-3100 recipients compared to 5 of 35 (14.3%) placebo recipients (p
We want breakthrough status... it speeds up the entire process, Orphan just means it is a really rare disease, HPV is relatively speaking pretty common. However their are no cures for it... hints we want breakthrough status.
Natural regression is usually seen in 9 months for HPV hints the length of the study. That's a tough question to answer since cancerous cells come and go all the time. However the immune system is capable of getting rid of these.
You're very close in your assessment, look at the confidence level... .025 is what tells me that the results weren't by chance. Most of the time .05 is the standard...
When it beats the placebo at a .025 confidence level you're onto something... The regression is nice, but the fact that VGX-3100 showed more regression at that high of a confidence level shows, the results were not by chance.... :)
Congrats to INO management, employees, and trial participants. It is neat to be watching the birth of a new technology that uses the immune system to kill off infections and cancerous cells. I'm proud to be a part of it, but even more proud of the fact that this company will be saving lives one day.
VGX-3100 WILL NOT BLOW Gardasil out of the water, Gardasil is used as a preventative, if someone already has HPV, Gardasil will have no effect on them and that is where VGX-3100 comes in... If successful VGX-3100 will be the first and only therapeutic ever made to treat HPV...
Gardasil = Prevents HPV, but does not cure it
VGX-3100 = Cures HPV, but does not prevent it
Hey crew, with earnings eight full days away I was wondering what your predictions will be. Do you think we will show a profit this quarter and if so by how much? I am guessing between .15-.25 cents a share.
You haven't been around INO long have you? Yes the Bill and Melinda Gates foundation have given INO money.
I have been monitoring this stock for a little while and have a few questions that I'm hoping a long can answer.
1. My Calculations are based off a 10% market capture with Zalviso which would mean a potential 1.5 million patients per year. So at $150 per patient x 1.5 million the gross revenue would be $225 million. With margins around 70% that would be $157 million Ebita. Are these numbers similar to your estimates?
2. There are 70 million surgeries per year, why are executives only saying the market is 10-12 million? I've been scratching my head on this,.
Many of these Analyst have their own agenda. I can think for myself just as well if not better than they can. Do I agree that MNKD is overvalued at this exact moment? Absolutely! No sales, no partnership, no distribution plan.
But if you look at a time horizon between now and the next 2 months, when they have a partner, a distribution plan, and future sales estimate, they then become tremendously undervalued at this moment...